Search PubMed⌕ Search

Biomedical subjects

M W Adler

Publications and source records attributed to M W Adler.

At least 37 records · Page 2Linked to original sources
PubMed1998

Characterization of kappa-opioid receptor transcripts expressed by T cells and macrophages.

We have found that the immature T cell lines R1.1 and DPK and the macrophage lines P388D1 and WEHI-3 also express kappa-opioid receptor (KOR) mRNA. Characterization of the KOR transcripts in both brain tissue and these T cells has revealed both the normal full-length as well as a truncated form of the mRNA. Our results show that the truncated transcript lacks the second exon. Primary macrophages express this truncated form of the transcript in the absence of detectable levels of the full-length form. These results suggest a degree of heterogeneity in the expression of the opioid receptors which has not previously been reported.

Animals↗
PubMed1998

An evaluation of partner notification for HIV infection in genitourinary medicine clinics in England.

OBJECTIVE: To evaluate the feasibility and effectiveness of a standardized HIV partner notification programme within genitourinary medicine clinics in England. DESIGN: A prospective survey of HIV partner notification activity over a 12-month period. SETTING: Nineteen genitourinary medicine clinics in England. PATIENTS AND PARTICIPANTS: A total of 501 eligible HIV-positive patients (either newly diagnosed or with whom partner notification had not been undertaken previously) seen during the study period. MAIN OUTCOME MEASURES: The numbers of partners named by patients, and the number of contacts notified, counselled and HIV-tested. RESULTS: Information on overall partner notification activity was obtained by reviewing available medical records of 471 patients; 353 (75%) had discussed partner notification with a health-care worker during the study period and 197 (42%) had undertaken partner notification. Detailed information on outcomes was obtained for only 70 patients who named 158 contacts as being at risk of acquiring HIV. Although 71 (45%) contacts were eventually notified, only 28 were subsequently seen in participating clinics. Almost all contacts (n = 27) requested HIV counselling and testing, and five were diagnosed HIV-positive. Patient referral was the most popular notification method chosen. CONCLUSIONS: This study illustrates some of the practical difficulties that limit HIV partner notification within genitourinary medicine clinics. These include health-care workers' misgivings about undertaking partner notification, insufficient locating information to identify contacts, and migration of newly diagnosed patients, which prevents continuity and completion of notification. Nevertheless, HIV partner notification uncovered previously undiagnosed HIV infections. Further work needs to be undertaken in staff training and policy implementation if higher rates of partner notification and outcome measurements are to be achieved.

Adolescent↗
PubMed1998

CCK(B) receptors in the periaqueductal grey are involved in electroacupuncture antinociception in the rat cold water tail-flick test.

Cholecystokinin octapeptide (CCK-8) (0.25-2.0 ng), the CCK(A) receptor antagonist L-364,718 (60-100 ng) or the CCK(B) receptor antagonist L-365,260 (0.3125-1.25 ng) was administered into the periaqueductal grey (PAG) of male SD rats. The antinociceptive effect induced by electroacupuncture (EA) stimulation of different frequencies was then measured by the cold water tail-flick (CWT) test. The results showed that (1) microinjection of CCK-8 into the PAG can significantly block the antinociceptive effect induced by all frequencies of EA stimulation. The effectiveness of the blockade was 100 > 2 Hz. In addition, CCK-8 blocks the antinociception seen following termination of the electrical stimulation at 100 Hz; (2) microinjection of L-365,260 (1.25 ng) into the PAG significantly increased the 100 Hz EA antinociceptive effect but not the 2 Hz EA antinociceptive effect and microinjection of L-364,718 into PAG did not affect either 2 or 100 Hz EA antinociception. These results demonstrate that CCK-8 in the PAG can antagonize the antinociceptive effect induced by EA stimulation, and the CCK effect is likely to be mediated by the CCK(B) receptor, but not the CCK(A) receptor.

Animals↗
PubMed1998

Effect of a mu-selective opioid antagonist on CCK-8-induced changes in thermoregulation in the rat.

We examined the effects of I.C.V. injection of CCK-8 alone and in combination with CTAP, a mu-selective antagonist, on brain surface temperature (Tb), oxygen consumption (VO2), and heat exchange (Q) in unrestrained male S-D rats at an ambient temperature of 20 +/- 0.5 degrees C. CCK-8 (300 ng, I.C.V.) produced hyperthermia (deltaTb: 0.86 +/- 0.22 degrees C) lasting for 30-60 min, which was associated with an increase in VO2 (1.42 +/- 0.28 ml/g/h). There was an increase in Q (1.87 +/- 1.2 cal/g/h) beginning 15 min after injection and lasting for 60 min. The CCK-8-induced hyperthermia was attenuated by a postinjection increase in Q. During the 60-120 min postinjection period, VO2 and Q returned to baseline followed by the return of Tb to preinjection levels. CCK-8-induced increases in Tb, Q, and VO2 were blocked by pretreatment with CTAP (0.75 nmol, I.C.V.) 15 min earlier. CTAP alone did not significantly affect deltaTb, deltaVO2, and deltaQ. These results suggest that, within the thermoneutral zone, the thermoregulatory effects of CCK-8 in the rat involve participation of mu-opioid receptors.

Analysis of Variance↗
PubMed1997

Interaction of cholecystokinin and somatostatin with a selective mu-opioid agonist and mu- and kappa-antagonists in thermoregulation.

We examined the effects of intracerebroventricular (i.c.v.) injections of cholecystokinin-octapeptide (CCK-8) and somatostatin (SST) and the interactions of these neuropeptides with the selective opioid antagonists, CTAP (mu) and nor-BNI (kappa) and the mu-agonist, PL017, on body temperature (Tb) of the rat at normal ambient temperature (21 +/- 0.5 degrees C). CCK-8 produced short-lasting (15-60 min), dose-related increases in Tb in a dose range of 20 to 900 ng but did not change the Tb at lower doses (0.1-2 ng). Lower doses of SST (1 and 2 micrograms) produced hyperthermia (30-60 min) and a higher dose of SST (10 micrograms) caused hypothermia (30-45 min). PL017 (1 microgram, i.c.v.), alone and in combination with CCK-8, produced hyperthermia. The CCK-8 (300 ng)-induced hyperthermia was blocked by pretreatment of rats with CTAP (1 microgram, i.c.v.), suggesting that the higher doses of CCK-8 increase Tb through the interaction with mu-receptors or the enhancement of release of endogenous opioids acting on the mu-receptor. The hyperthermia elicited by a lower dose of SST (1 microgram) was prevented by pretreatment with CTAP but not with nor-BNI (1 microgram, i.c.v.). Pretreatment with nor-BNI blocked the higher dose (10 micrograms) of SST-induced hypothermia. PL017 or CTAP did not prevent the hypothermic effect of that dose of SST. These results indicate that a lower dose of SST (1 microgram) stimulates the mu-receptor (directly or indirectly) and a higher dose (10 micrograms) interacts with the kappa-receptor in regulation of Tb. Thus, the effects of both CCK-8 and SST on Tb appear to involve the endogenous opioid system.

Animals↗
PubMed1997

Inhibition of T cell superantigen responses following treatment with the kappa-opioid agonist U50,488H.

Previous work in our laboratory has shown that cytokine production by primary murine macrophages, and macrophage cell lines, is inhibited following treatment with the kappa-opioid agonist U50,488H. Furthermore, we have found that the participation of both accessory cells and T cells in an antibody response is suppressed by this compound. We have utilized the superantigen staphylococcal enterotoxin B (SEB) to further examine the effects of U50,488H on accessory and T cell function. The results showed that the proliferative response of lymph node T cells to SEB presented by activated macrophages was significantly inhibited by the kappa-opioid agonist at concentrations as low as 100 nM. However, suppression of the T cell response to SEB presented by resting macrophages required 100 times the concentration of U50,488H. On the other hand, the production of IL-2 in response to lymph node T cell stimulation with SEB was not altered by the opioid treatment. Additional experiments utilizing the opiate antagonist naloxone and the kappa-selective antagonist nor-binaltorphimine (norBNI) were performed in order to further characterize the opioid receptor involved in the suppressive activity of U50,488H. Results showed that both naloxone and norBNI were able to block the inhibitory activity of U50,488H. Further analysis showed that the proliferative response of thymic T cells was more sensitive to the effects of U50,488H, and the response with both activated and resting macrophages was suppressed. In addition, the production of IL-2 by the thymic T cells was also inhibited by the opioid treatment. The mechanism of suppression of superantigen-induced T cell responses is discussed.

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cycloh↗
PubMed1997

Morphine alters macrophage and lymphocyte populations in the spleen and peritoneal cavity.

We have previously shown that subcutaneous implantation of a 75 mg morphine pellet results in suppression of the ability of murine splenocytes to mount an antibody response to sheep red blood cells, due in part to a reduction of macrophage function. The present studies used flow cytometry to examine whether the decrement in macrophage function in the spleens of morphine-treated mice results from a reduction in macrophage numbers. Parallel analysis was carried out on non-elicited peritoneal cells. In the spleen, morphine resulted in a reduction in the relative proportion of macrophages and B-cells, with a concomitant increase in the proportion of T-cells. Alteration in the ratio of CD4+ to CD8+ T-cells was not observed. In contrast, in the peritoneal cavity, morphine increased the number of macrophages and reduced the number of B-cells. Naltrexone blocked all of the changes in cellular composition. These results support the conclusion that an important mechanism in the immunosuppression seen in the spleens of mice implanted with morphine pellets is a differential reduction in the number of macrophages and B-cells as compared with T-cells. Further, these studies show that subsets of cells of the immune system are differentially affected by morphine in different anatomical compartments.

Administration, Cutaneous↗